SCHEMBL17080357

SCHEMBL17080357

N#Cc1cnc2c(Br)cnn2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 2/20 0.47
PRKAG1 P54619 2/20 0.47
PRKAA2 P54646 2/20 0.47
PRKAA1 Q13131 2/20 0.47
PRKAG3 Q9UGI9 2/20 0.47
PRKAG2 Q9UGJ0 2/20 0.47
PRKAB1 Q9Y478 2/20 0.47
KDR P35968 2/20 0.45
ABL1 P00519 1/20 0.45
AXL P30530 1/20 0.44
CDK2 P24941 2/20 0.44
MAP4K4 O95819 2/20 0.44
PLK4 O00444 1/20 0.44
AURKA O14965 1/20 0.44
DYRK3 O43781 1/20 0.44
NTRK1 P04629 1/20 0.44
INSR P06213 1/20 0.44
CDK1 P06493 1/20 0.44
FGFR1 P11362 1/20 0.44
FLT1 P17948 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24767177 0.79 KDM4E (0.43) CDK2KDM4EHSD11B1KCNJ5ALDH1A1
SCHEMBL31470548 0.79 SMPD3 (0.44) KDRABL1CDK2HTTKDM4E
SCHEMBL3754835 0.75 PRKAB2 (0.54) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL10258993 0.75 KDM4E (0.40) KDM4EHSD11B1KCNJ5IRAK4EGLN2
SCHEMBL24508343 0.75 HSD11B1 (0.52) KDM4EHSD11B1ALDH1A1IRAK4
SCHEMBL24508342 0.72 HSD11B1 (0.53) HSD11B1IRAK4
SCHEMBL29791699 0.72 KCNJ5 (0.44) KDM4EHSD11B1KCNJ5MEN1NPC1
SCHEMBL12517707 0.72 PRKAB2 (0.51) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL2284618 0.72 PRKAB2 (0.65) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL2281774 0.72 PRKAB2 (0.51) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024020084-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-25 WO disclosed
EP-3313844-B1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-26 EP disclosed
EP-3313844-B1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-26 EP disclosed
CN-108026099-B Heteroaryl substituted aminopyridine compounds 百时美施贵宝公司 2020-07-10 CN disclosed
US-10202390-B2 Heteroaryl substituted aminopyridine compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-12 US disclosed
US-10202390-B2 Heteroaryl substituted aminopyridine compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-12 US disclosed
US-20180179213-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2018-06-28 US disclosed
US-20180179213-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2018-06-28 US disclosed
US-20180179213-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2018-06-28 US disclosed
EP-3313844-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS Bristol-Myers Squibb Company (US) 2018-05-02 EP disclosed
US-9896454-B2 Microbiocidal heterobicyclic derivatives SYNGENTA PARTICIPATIONS AG (CH) 2018-02-20 US disclosed
EP-3114127-B1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2017-11-29 EP disclosed
US-20170073346-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2017-03-16 US disclosed
EP-3114127-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES Syngenta Participations AG (CH) 2017-01-11 EP disclosed
WO-2016210037-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-29 WO disclosed
WO-2015132133-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2015-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202390-B2 Heteroaryl substituted aminopyridine compounds IRAK4, IRAK3, IRAK2 PRKAB2 1974/4885PRKAG1 2047/4885PRKAA2 508/4885
US-20180179213-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS IRAK4, IRAK3, IRAK2 PRKAB2 1974/4885PRKAG1 2047/4885PRKAA2 508/4885
US-20170073346-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES MSR1, C1R, C3AR1 PRKAB2 4315/4885PRKAG1 4219/4885PRKAA2 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.